The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to provide a greater substantial decrease in body mass and enhance metabolic health, pa